Candida vaccine: Additional Phase I data

Data from 6 healthy volunteers in the low-dose cohort of a Swiss Phase I trial showed that a booster vaccination with PEV7 given 14 months after the last of 3 primary immunizations produced detectable anti-SAP2 antibodies in the serum of 5 subjects and in vaginal/cervical secretions of 4 subjects at 1 month after the booster injection. Subjects initially received monthly intramuscular injections of 10 µg PEV7 for 3 months. At 14 months after the third immunization, serum and vaginal antibody titers returned to baseline at which time subjects received a single 10 ug booster injection of PEV7. ...